CI

At a glance

ClinicalIndex Comparison Record
Phase 2Not Yet Recruiting· 318 target
Drug / intervention
CVL006 combined with pemetrexed and carboplatin +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT07157956
NCT07157956Phase 2Not Yet Recruiting
CompareCT.gov

Phase I/II Clinical Study of CVL006 Combination Therapy in Advanced Solid Tumors

Convalife (Shanghai) Co., Ltd.·interventional·Posted Sep 5, 2025·Updated Sep 5, 2025

In Brief

A Phase 2 clinical trial evaluating CVL006 combined with pemetrexed and carboplatin, CVL006 in combination with SKB264, and 2 other interventions for Advanced Solid Tumor. Not yet recruiting, targeting 318 participants across 1 site.

Detailed Summary

This study is a multi-center, open-label, dose-escalation and dose-optimized phase I/II clinical trial. Objective: To determine the safety, tolerability, PK characteristics and preliminary efficacy data of CVL006 combined with pemetrexed + carboplatin/SKB264/ DS-8201a/ Enfortumab Vedotin in patients with advanced solid tumors.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced Solid Tumor
CountriesChina
Collaborators--

Timeline

Phase 2Not Yet Recruiting
2026202720282029
First PostedSep 5, 2025
Enrollment StartSep 10, 2025
Primary CompletionAug 12, 2028
Study CompletionDec 30, 2028
TodayJul 1, 2026
Enrollment to primary: 2.9 yearsPosted 10 months agoPrimary completion in 2.1 years

Interventions

CVL006 combined with pemetrexed and carboplatindrug

CVL006 combined with pemetrexed and carboplatin

CVL006 in combination with SKB264drug

CVL006 in combination with SKB264

CVL006 in combination with DS-8201drug

CVL006 in combination with DS-8201

CVL006 in combination with Enfortumab Vedotindrug

CVL006 in combination with Enfortumab Vedotin